CORC

在结果中检索

CORC

浏览/检索结果: 共30条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma 期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 9
作者:  Zhou, Yu-bo;  Zhang, Yang-ming;  Huang, Hong-hui;  Shen, Li-jing;  Han, Xiao-feng
收藏  |  浏览/下载：93/0  |  提交时间：2021/11/04
A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression 期刊论文
CANCER RESEARCH, 2020, 卷号: 80, 期号: 3, 页码: 536-548
作者:  Wang, Yingcong;  Huang, Jing;  Li, Bo;  Xue, Han;  Tricot, Guido
收藏  |  浏览/下载：54/0  |  提交时间：2020/07/01
Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma 期刊论文
Bioorganic & medicinal chemistry letters, 2018
作者:  Zhou, Ruolan;  Fang, Shaoyu;  Zhang, Minmin;  Zhang, Qingsen;  Hu, Jian
收藏  |  浏览/下载：97/0  |  提交时间：2019/01/08
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma 期刊论文
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 卷号: 11
作者:  Zhao, Wan-Hong;  Liu, Jie;  Wang, Bai-Yan;  Chen, Yin-Xia;  Cao, Xing-Mei
收藏  |  浏览/下载：3/0  |  提交时间：2019/11/26
Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data 期刊论文
BIOMED RESEARCH INTERNATIONAL, 2018
作者:  Li, Shuo;  Meng, Xiang-Yu;  Maman, Souraka Tapara Dramani;  Xiao, Yong-Nong;  Li, Sheng
收藏  |  浏览/下载：1/0  |  提交时间：2019/12/05
Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma 期刊论文
2018, 卷号: 40, 期号: 7, 页码: 1122
作者:  Zhang, Tian-tian[1];  Wang, Sen[1];  Wan, Ning[2];  Zhang, Li[3];  Zhang, Zugui[4]
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/13
Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from t 会议论文
BLOOD, 2018-11-29
作者:  Fu, Weijun;  Lu, Jin;  Jin, Jie;  Xu, Yan;  Wu, Depei
收藏  |  浏览/下载：6/0  |  提交时间：2020/01/03
Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from t 期刊论文
2018, 卷号: 132
作者:  Fu, Weijun;  Lu, Jin;  Jin, Jie;  Xu, Yan;  Wu, Depei
收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03
A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma 期刊论文
2018, 卷号: 41, 期号: 10, 页码: 1008-1014
作者:  Hou, Jian;  Qiu, Lugui;  Zhao, Yaozhong;  Zhang, Xuejun;  Liu, Yan
收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03
The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells 期刊论文
ONCOLOGY REPORTS, 2017, 卷号: 38, 期号: 1, 页码: 488-496
作者:  Chen, Gege;  Xu, Zhijian;  Chang, Gaomei;  Hou, Jun;  Hu, Liangning
收藏  |  浏览/下载：24/0  |  提交时间：2019/01/08

©版权所有 ©2017 CSpace - Powered by CSpace